StemCell Therapy

England is in crisis. They lost a beloved figurehead this month but for decades prior were losing scientific ground. If you look for the home of the modern organic food and anti-vaccine movements, you find their nexus in 1990s England.

The primary royal behind those beliefs is now King Charles III.

In order to manage the $28 billion he inherits (tax-free, paying taxes only applies to peasants in England)(1) he will have to give his $1.5 billion estate to his son, the new Prince of Wales, William (also tax free) but the Prince is not only taking over during a time when Brits are wondering why they still care about a throne that hasnt been relevant in hundreds of years, he is taking over at a time when being anti-science is no longer fashionable for progressive elites.

Though it was recently the darling of the intelligentsia, and Prince Charles longed to belong in that circle, anti-vaccine sentiments have become proletariat since COVID-19. The war on science when it comes to food harms a lot more people worldwide each year than the pandemic did. Hundreds of thousands of kids could stop going blind each year with Golden Rice but elites like King Charles III give money to groups that block its implementation.

Prince William could start to gain back some credibility for the family by jettisoning the organic food fetish of his father. Organic food, like the anti-vaccine movement, is a relic of 1990s England. Dr. Andrew Wakefield set off the modern anti-vaccine craze the same way that English environmental activists set off the Frankenfood one. Now supplements, wellness, and organic are all giant businesses based on exploitation of famous names who wanted to impress their elite friends

The world should have passed the anti-vaccine and anti-food movement by but they persist in large part because of the new British monarch and his quasi-American royalty of American Democrats counterpart, Robert F. Kennedy, Jr.(2)

Its easy to embrace science, especially in light of their history making changes when it was needed. They changed their name to Windsor from Saxe-Coburg and Gotha during World War I to help commoners forget the British royal family is German during a time that Germany was shooting at English men in Europe. Given that public relations success, they can certainly change their tune when it comes to science.

Perhaps due to an infusion of new blood outside the shockingly limited pool drawn from during the 19th and 20th centuries, Prince William seems to be a more genetically gifted thinker than his father. He can show it by embracing the modern world, where food and medicine are embraced.(3)

He doesnt actually have to divest from the farm, that is just me getting attention in a title. It is enough if he acknowledges that having peasants toil for his carrots only using specially labeled toxic pesticides is a pastime for the rich, and not a way to feed the world.

(1) The same way California Governor Gavin Newsom doesnt want people who make over $2 million each year to pay higher taxes to subsidize the electric cars the Governor insists Uber drivers need to buy. High taxes are for the middle class and the poor, not the donors he will need in order to fail running for President in 2024.

(2) Nothing looks more hypocritical than people on the left in England and the US suddenly endorsing vaccines when just two years ago they opposed them. It instead reeks of politics, and politics need to be a no-no for the new generation of British royals, lest they be relegated to the name recognition of the Queen of the Netherlands, whoever that is.

(3) and not just engage in publicity stunts about energy costs that are squarely the blame of the government his father now seeks to lead.

Hank Campbell founded Science 2.0 in 2006, and writes for USA Today, Wall Street Journal, CNN, and more. His first book,Science Left Behind,was the #1 bestseller on Amazon for environmental policy books. Follow Hank on Twitter@HankCampbell

A version of this article was originally posted atScience 2.0and is reposted here with permission. Science 2.0 can be found on Twitter@science2_0

See the original post here:
Viewpoint: Will King Charles abandon his kooky ideas about agriculture and help accelerate Britain's embrace of sustainable biotechnology tools? -...

Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. So if youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors.

Aurinia is a pharmaceutical company focused on developing therapies for patients with rare and neglected diseases. The companys lead product, voclosporin, is designed to treat lupus nephritis, a kidney inflammation caused by systemic lupus erythematosus (lupus). The company has a robust business model, and voclosporin effectively treats lupus nephritis in several clinical trials. Aurinia is expected to begin Phase III clinical trials for voclosporin in early 2022. Aurinia Pharmaceuticals is currently trading at $4.56 per share. The company has a market cap of $1.03 billion and a price-to-book ratio of 1.44. The company is expected to have annual revenue of $784 million in 2022.

Verve is a pharmaceutical company focused on developing therapies for rare central nervous system (CNS) disorders and diseases of the eye. The companys lead product, a treatment for retinal vein occlusion (RVO), is currently in Phase III clinical trials. Verve was formed due to a merger between Neurocrine Biosciences and Ferrokinetics. After the two companies merged, the company was renamed Verve Therapeutics and continued to work on the same RVO treatment. Verves RVO treatment is expected to be commercially available in 2022. Verve Therapeutics is currently trading at $3.63 per share. The company has a market cap of $1.32 billion and a price-to-book ratio of 0.99. The company is expected to have annual revenue of $539 million in 2022.

Neurocrine is a biopharmaceutical company focused on developing therapies for severe and rare diseases. The companys lead product, INGREZZA, is destructive dyskinesia (TD), a movement disorder characterized by involute notary facial, arm, and leg movements. TD is a severe and long-term condition that is often associated with the use of certain psychiatric medications. INGREZZA is effective in treating TD in several clinical trials. Neurocrine was formed due to a merger between Vercure Pharmaceuticals and Ferrokinetics. After the two companies merged, the company was renamed Neurocrine Biosciences. Neurocrine Biosciences is currently trading at $26.37 per share. The company has a market cap of $5.37 billion and a price-to-book ratio of 1.69. The company is expected to have annual revenue of $1.13 billion in 2022.

Regenxbio is a biopharmaceutical company focused on developing immuno-oncology therapies and bispecific antibodies (Bi-SBIs). Immuno-oncology treatments are being developed to treat various cancers by activating the immune system. Bi-SBIs are engineered to bind to two different targets at the same time. The companys lead product, RG101, is being developed as a treatment for diabetic macular edema (DME), a degenerative eye disease that affects individuals with diabetes. RG101 is effective in treating DME in several clinical trials. In addition, the U.S. Food and Drug Administration (FDA) has also granted Breakthrough Therapy Designation designation. Regenxbio is currently trading at $27.09 per share. The company has a market cap of $2.39 billion and a price-to-book ratio of 4.24. The company is expected to have annual revenue of $1.32 billion in 2022.

Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. If youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors. Now its time for you to decide which biotech stocks to buy in 2022. Remember that these are just some suggestions, so do your research before investing in any company or store.

Go here to see the original:
Top Biotechnology Stocks to Buy in 2022 - Best Stocks

There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and quality of life.

People often bequest money in their will to these organisations, donate after a loved one has been struck down by a particular illness or at funerals ask for donations to a an organisation in lieu of traditional flowers.

And while these organisations do great work, what about considering investing directly in medical companies for the greater good? Biotechnology investing is one sector which stands out for not only potential to deliver quality returns but also contribute positively to society.

Australias biotech representative body AusBiotech CEO Lorraine Chiroiu told Stockhead many of us unfortunately have a personal connection to catastrophic disease and, motivated by our experiences, are seeking avenues to put our philanthropic and investment dollars where we can make a meaningful and sustainable difference.

AusBiotech is receiving increasing enquiries from people who want to gift, bequeath or invest in a way that gives the best chance of new medical treatments and cures making their way to people experiencing disease, she said.

For example, we recently received a call from a father whose only son had passed away from cancer. Nobly, he wanted to make a purposeful investment into a company working to provide treatment for the disease that took his son in the hope that other families wouldnt have to go through the same suffering as his family.

Indeed many biotech companies have been founded by grieving family or friends that are passionate about finding a cure for a disease that took their loved one too soon.

Chiroiu said biotechnology companies are the vehicles that move medical research along the translation and commercialisation pathway to patients.

Companies operating in the life science and medtech sectors are in a unique position where business foundations are often influenced by a strong value-driven purpose one that offers positive social impact as the company develops life-saving and life-enhancing technologies.

Focusing clearly on patient impact, social good is codified into biotech companies DNA and are a great avenue for ethical investors to consider diversifying their portfolio.

She said we are living in an age of profound acceleration in medicinal discoveries and healthcare options, as well as a time that the Covid-19 pandemic has brought biotechnology especially in the form of vaccines into sharp focus.

As we emerge from the pandemic, the chronic health challenges and increasing burdens of disease associated with ageing populations around the world has many of us wondering how we can help move medical research from the bench to the bedside the answer is via business, she said

Australias biotech industry is on a strong growth trajectory, through substantially increasing numbers of organisations. Figures released by AusBiotech show the sector has grown 43% since 2019 and 60% since 2017.

Amid a thriving and expanding biotech industry in Australia, feeding the need for commercialisation, clinical development and growth is key and the diversity of investment sources remains a pressing issue, Chiroiu said.

Capital is the lifeblood of these companies and in response to this increasing need, AusBiotech has bolstered its investment program with a goal that Australian and overseas investors increasingly see Australian life sciences research and small-to-medium enterprises as viable and attractive investment options.

Global X head of investment strategy Blair Hannon told Stockhead biotechnology investing is well positioned to tick the boxes of environmental, social and governance (ESG) considerations of both institutional and retail investors.

For environmentally minded investors, the biotech industry has a low carbon footprint as most work is research-driven and not energy-intensive and as such, adding biotech exposure can help lower the average carbon footprint of a portfolio, Hannon said.

The biotech industry is highly regulated as measured by the S&P Biotechnology Select Industry Index and is free of any violators of the UN Global Compact (UNGC), which is a widely-followed benchmark of corporate good behaviour.

Hannon said alongside many other sectors, biotechs are striving towards ESG targets. Whilst a diversified biotech ETF such as its S&P Biotech ETF (ASX:CURE) is not explicitly tracking an ESG framework, Hannon noted many biotech companies within the fund focus on social good as their technology aims to aid people from all walks of life with disease treatments or even eradication.

Prescient Therapeutics (ASX:PTX)CEO and managing director Steven Yatomi-Clarke told Stockhead bringing life-changing therapies to patients is an incredibly challenging undertaking that requires resources and resilience.

PTX is at the forefront of game-changing personalised cancer treatments with a strong pipeline of promising therapies. The company has a growing list of collaborations with leading cancer organisations globally including Peter McCallum Cancer Centre, University of Texas MD Anderson Cancer Center, Yale, Oxford and UPenn.

Companies brave enough to take on this challenge call on investors to fund the research and development at least, until they become profitable, he said.

But at Prescient, when we accept a dollar from an investor, we are focussed on growing that into more than one dollar.

He said in the last two years, Prescient has spent around $8m of shareholder funds, but through consistent delivery of milestones and progress, the company has translated this $8m into over $100m of shareholder value.

So shareholders have enjoyed a handsome financial return, but additionally, they can be satisfied in knowing that their investment has resulted in incredibly exciting progress to create therapies that we believe are going to change lives.

AusBiotech is aiming to educate potential investors in life sciences companies about the unique ecosystem, through in-person events such as its AusBioInvest 2022 in Perth in October as well as plain English resources including The Guide to Life Sciences Investing

At Stockhead, we tell it like it is. While Prescient Therapeutics is a Stockhead advertiser, it did not sponsor this article.

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

You might be interested in

See the original post:
Biotechnology investing for the social good making money and a difference - Stockhead

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:

Interested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event.

About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.

Media Contactpress@nautilus.bio

Investor Contactinvestorrelations@nautilus.bio

Go here to read the rest:
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit - GlobeNewswire

The U.S. Department of Health and Human Services (HHS) today announced actions the department will take following theExecutive Ordersigned September 12, 2022 by President Biden launching a National Biotechnology and Biomanufacturing Initiative (NBBI).

This initiative will help drive research and development, improve access to quality federal data, grow domestic manufacturing capacity, expand market opportunities for biobased products, train a diverse and skilled workforce, streamline regulatory processes for products of biotechnology, advance biosafety and biosecurity to reduce risk, protect the U.S. biotechnology ecosystem, and build a thriving and secure global bioeconomy with partners and allies.

In its implementation of the Executive Order, HHS intends to leverage biotechnology and biomanufacturing in order to achieve medical breakthroughs, reduce the overall burden of disease, and improve health outcomes. HHS will lead the U.S. government in strategically advancing biosafety and biosecurity innovation as part of a growing bioeconomy, to ensure biotechnology research and development and biomanufacturing infrastructure break new ground while reducing risk.

Building on the departments successes at bolstering the resilience of the domestic public health supply chain and on continued collaboration and partnership with the American private sector, HHS welcomes a whole-of-government approach to secure U.S. leadership and stewardship of an equitable, safe, and secure bioeconomy. The COVID-19 pandemic has highlighted the departments ability to foster innovative biotechnological treatments, diagnostics, and vaccines swiftly and safely as well as HHS ability to facilitate a more flexible regulatory environment in such circumstances.

With the launch of NBBI, HHS will:

More:
Fact Sheet - HHS.gov

Thank you very much to Jake and for the whole White House team here for the amazing work youve done to get us to this point.

At the Defense Department, this moment in the bioeconomy matters for a lot of reasons.

First, we know that biotechnology and biomanufacturing have transformative potential for our mission at DoD to defend the nation.

It helps us improve capabilities, solve logistics challenges in ways that are sustainable, to Secretary Granholms point, and to protect our people.

And of course we know that strategic competitors like China are themselves prioritizing these technologies. They want to displace U.S. leadership and they want to challenge our competitiveness.

Under Secretary Austins leadership at DoD, we know, though, that we have what it takes here in the U.S. to really footstomp what Jake said earlier we have here, the ability, the ingenuity, the resolve to lead the way, and we have the right kind of innovation ecosystem to make it happen.

So, what can DoD do to help in this space?

Well, over the next five years, DoD will be investing nearly $1.5 billion dollars to expand U.S. bioindustrial manufacturing infrastructure, strengthen biosecurity and cybersecurity at those facilities, and use biotechnology to bolster our supply chains.

The goal, really, is to help be a key catalyst for a domestic bioindustrial manufacturing base, and more quickly turn basic and applied research into operational prototypes and reliable, reproducible products that can be made at scale.

We believe these investments will incentivize biotech innovation and manufacturing capacity for products important both for commercial and defense supply chains, such as critical chemicals for lubricants, energetics, and fuels.

This investment really builds on a history of groundbreaking DoD investment in the biotech space.

You can think about DARPAs work 10 years ago that kickstarted a rapid-response mRNA vaccine platform for infectious diseases, or more recently funding that the department has provided for some of the early wastewater assessment work for COVID, which has great applications for force protection against the coronavirus or future pandemics and has offered spin-off potential for U.S. and overseas communities grappling with biothreats.

And I also understand I think we have here with us today two of DoDs nine Manufacturing Innovation Institutes, BioMADE and BioFabUSA, so thank you to them for all the great work theyre doing.

Going forward, we expect our focus on biotechnology and biomanufacturing to be transformative for what we do at DoD for our forces.

Let me just give you an example of some of the things that are already happening:

Those examples arent science fiction, I think as the folks in this room know. Like the institutions, companies and agencies represented here today, theyre proof of one of Americas greatest strategic assets and thats our incredibly-vibrant innovation ecosystem. Its the envy of the world, and we want to help keep it that way.

Thanks very much.

More:
Deputy Secretary of Defense Dr. Kathleen Hicks' Remarks at the White House Summit on Biote - Department of Defense

President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.

President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.

The Democrat was in Boston for an address deliberately echoing John F. Kennedy's famous 1962 "Moonshot speech" in which he called for landing an American on the lunar surface -- something achieved in 1969, after his assassination.

This time, Biden is pushing government-backed efforts to coordinate and fund treatment of cancer, search for cures and generally to prevent the disease through better public health.

Cancer remains the number two cause of death after heart disease and Biden said his Cancer Moonshot can halve death rates over the next 25 years.

"I know we can do this together, because I know this: there's nothing, nothing, nothing beyond our capacity or ability if we work together as the United States of America," he said.

Biden said that as in 1962, when the country was in the thick of the Cold War and domestic tensions were high over civil rights, the United States today is at an "inflection point."

And like Kennedy with his Moon program, Biden said he wanted to set "a national purpose that could rally the American people in a common cause."

- Backing from JFK's daughter -

Caroline Kennedy, daughter of the assassinated JFK and now US ambassador to Australia, said her father had defied the doubters in the 1960s, when "scientists weren't sure even that a Moon landing on the surface of the Moon was possible."

Kennedy, however, "understood the power of the idea" and saw the project as a way to unite the country. "No one embodies that spirit more than President Joe Biden," she said. "As president, he has restored the soul of America."

The battle against cancer is personal for Biden: his son Beau died of brain cancer in 2015 when Biden was vice president to Barack Obama.

Biden noted that cancer "does not discriminate..., it doesn't care if you're a Republican or Democrat."

"I give you my word as a Biden: this Cancer Moonshot is one of the reasons why I ran for president."

The linkage to the Moon program also sought to add to Democratic momentum ahead of November's midterm congressional elections where the Democrats face the possibility of a Republican sweep in Congress, severely complicating the last two years of Biden's first term.

- Change the trajectory -

Biden said his plan will push for cures and ways to manage cancer, turning "more cancers from death sentences into chronic diseases that people can live with."

"We know we can change the trajectory," he said.

The president said he was harnessing funding but also government expertise in high-tech research similar to the defense industry, where public-private partnerships drive innovations in weaponry and other military needs.

A new agency named Advanced Research Projects Agency for Health (ARPA-H) and the White House's new "cancer cabinet" will "increase funding to break log jams and to speed breakthroughs," while getting entrepreneurs support from cutting edge scientists with NASA, the Pentagon and the energy department.

The goal is to "use all the assets we have," Biden said, and this "may require unusual partnerships."

- Biotech boost -

Earlier, Biden signed an executive order meant to bolster the trailblazing US biotech sector's efforts to take on growing commercial rivals in China.

The order brings federal support for "areas that will define US biotechnology leadership and our economic competitiveness in the coming decades," a senior Biden administration official told reporters.

The official said that while US biotech research leads the world, the industrial applications are increasingly in the hands of other countries.

"Unless we translate biotechnology innovation into economic and societal benefits for all Americans, other countries, including and especially China, are aggressively investing in this sector," posing a "risk," the official said.

The White House says the US biotech industry is on the cutting edge of medical advances -- recently seen in the rapid development of vaccines, tests and therapeutics to help manage the Covid-19 pandemic -- but that the potential scope goes much further.

The official speaking to reporters cited studies suggesting that "before the end of the decade, engineering biology holds the potential to be used in manufacturing industry that accounts for more than one third of global output. That's equivalent to almost $30 trillion in terms of value."

Growing areas for biotech industry include new plastics and rubbers, jet fuel, and environmentally friendly fertilizers.

Excerpt from:
Biotechnology to the fore as Biden evokes US Moon mission in renewed cancer fight - HT Tech

Scope of the Global Nano Biotechnology Market

Nano Biotechnology Market Report that covers exclusive and analytical data through the span of Ten years between 2022-2032. This report is exclusive and encompasses in-depth analysis and industry insights on Nano Biotechnology Market. What you will get by reading the report is not just charts, bars, and analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest of your organization.

The QMI research report published on the Global Nano Biotechnology Market is an in-depth study of market share, value, and dynamics and is an extensive study of market trends. In addition, geometric surveys are used for predictive analysis, PESTLE analysis, SWOT analysis, and real-time analytics. This is a recent research study, covering the current COVID-19 impact on the global market.

The Nano Biotechnology market report also offers leading players along with a comprehensive strategic scenario pertaining to market volume and market promotion. The report delivers an in-depth market with detailed research on revenue growth and profit study. Also, various graphs are clearly used to offer the data format for an accurate study of facts and figures. The rapidly shifting market scenario and primary & future evaluation of the influence are featured in the research study.

Click here to get a sample of the premium report: https://www.quincemarketinsights.com/request-sample-84960?utm_source=sk/dj

Competitive Landscape: Global Nano Biotechnology Market

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecBioanalytics GmbH (Germany), Nanobiotix (France) and Dabur Pharma (India)

A brief study of the major market players and manufacturers has been extensively offered in the report to address several queries of clients and readers. The study is targeted to help in the various business decisions and key investment priorities of major stakeholders with a brief analysis of suppliers, distributors, manufacturers, and traders.

Similarly, in this report, clients are rendered important cues on providers landscape and their current competition strength, which highly influence the development of the global Nano Biotechnology market. Further, leading providers, manufacturing landscape, percentage splits, market revenues, breakdowns of the product scenario, and growth details are studied through primary as well as secondary sources.

Understanding Segmentation: Global Nano Biotechnology Market

The Nano Biotechnology market has been segmented as By Application (Pharmaceuticals, Medical Devies, Medical Research, Food and Agriculture) By Therapeutics (Dental Therapies, Cardiac Therapies, Orthopedic Therapies, Others)

The global Nano Biotechnology market report also gives major data on the basis of comprehensive market segmentation. The global Nano Biotechnology Market segment chapter delivers the company total revenue (financials), sales and revenue generated, price, industry share, production sites and services, and product launches.

This report divides the market into various segments on the basis of type, application, technology, as well as geographical regions. Likewise, the report delivers other data such as product consumption, manufacturing details, production capacity, and supply and demand analysis of the market. For the period 2023-2032, this report delivers the Nano Biotechnology sales, revenue, and market share of this market.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-84960?utm_source=sk/dj

Regional Analysis of the Global Nano Biotechnology market

The market report delivers a major regional spectrum for market scope, and studies, and analyzes each geographical section of the market. The report also offers a detailed research on major insights such as import, consumption, export, supply, and demand. This research study offers regional analysis for regions such as Europe (Germany, France, United Kingdom, Russia, and Italy), North America (United States, Canada, and Mexico), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina), and Middle East & Africa (UAE, Egypt, Saudi Arabia, and South Africa).

The report provides insights on the following pointers:

Market Penetration: Detailed information on the product portfolio of the key market players in the Nano Biotechnology market.

Product Innovation/Development: Comprehensive insights into the upcoming technologies, research, and development activities as well as the product launches in the market.

Competitive Assessment: Assessment of the market strategies, business segments and geographical regions of the leading market players.

Market Development: Detailed information about the growing markets. The report also studies the market for various segments across the geographies.

Market Diversification: Comprehensive information about the new product launches, recent development, untapped geographies, and huge investment made by the market.

Quantitative data:

1. Market Revenue and Growth Rate by Type (Historical and Forecast)2. Market Revenue and Growth Rate by Application, such as Food, Beverages, Pharmaceuticals, Industrial & Chemicals, Cosmetics & Personal Care, Agriculture, Others.3. Market Revenue, Growth Rate, Volume, Type, and Application by Each Country (History and Forecast)4. Revenue, Volume, and YOY Growth Rate by Player (Base Year).

This report provides: 1) An overview of the global market for Nano Biotechnology market and related technologies.2) Analysis of global market trends, yearly estimates, and annual growth rate projections for compounds (CAGRs).3) Identification of new market opportunities and targeted consumer marketing strategies for the global Nano Biotechnology market.4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-84960?utm_source=sk/dj

Conclusion

The market overview details includes the extensively classified insights procured through several sources. This market report also follows significant market drivers, challenges, and threats that influence the growth of this market. It is a professional and a thorough study that focuses on primary and secondary drivers, market share, major segments, and regional analysis.

Significant market policies have also been studied from the techno-commercial scenario for getting better outcomes. This research study provides quantified data for current market scenario, along with offering an evaluation of the key market players and their growth strategies.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Pune, Maharashtra

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Continued here:
Nano Biotechnology Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2032 - Digital Journal

Most of us are familiar with the propaganda aimed at glyphosate, the active ingredient in Roundup. For years, activists pushed fake news and disinformation about the seriously benign herbicide, mostly because it was associated with genetically modified crops. Francevowed to seriously curtail usewithin its borders. And now local governments around the U.S.,including New York City, are banning it entirely.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Consider Greenpeaces nonsensical opposition to genetically modified crops. The activist organizationhas promoted outright falsehoodsand lies about GMO crops online and in other formats for years. As a result some Southern African governments decided it was better to let their residents starvethan distribute GMO grainssent by other countries. And everyone knows thatGreenpeaces obstruction of Golden Rice [despite] a letter from 159 Nobel Laureatesbegging them to stop with the disinformation couldnt convince them.

Theres plenty of other examples, like GMO labeling, that I could point to. Unfortunately, were increasingly living in a post-truth world where most people only surround themselves with people they want to believe. And, if anything, its only getting worse. So while standing up to these coordinated attacks when they first develop on social media might not be fun and sexy, its more important than ever.

This is an excerpt. Read the original post here

View original post here:
Viewpoint: Here's how post-truth tactics became central to the anti-biotechnology playbook - Genetic Literacy Project

HARRISON, N.Y., Sept. 19, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer, announced today that preclinical data on ST101, the company's first-in-class peptide antagonist of C/EBP, were published online in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. The published data describe preclinical evidence to support the advancement of ST101 as a novel therapy for treating advanced solid tumors. The full manuscript titled "Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein ", can be found online here.

The data in the manuscript detail ST101-antagonism of CCAAT/Enhancer Binding Protein (C/EBP), a basic leucine zipper family transcription factor that is upregulated or overactivated in many cancers, resulting in gene transactivation that drives oncogenesis. ST101 binds C/EBP, preventing its dimerization and enhancing ubiquitin-proteasome dependent C/EBP degradation. ST101 exposure significantly decreases expression of C/EBP target genes including genes responsible for survival, transcription factors and cell cycle-related proteins. The result of ST101 exposure is potent, tumor-specific in vitrocytotoxic activity in cancer cell lines including glioblastoma, breast, melanoma, prostate, and lung cancer, while normal human immune and epithelial cells are not impacted. In vivoxenograft models indicate that ST101 exposure results in potent tumor growth inhibition or regression,both as a single agent and in combination studies.

"The publication of ST101 in Molecular Cancer Therapeutics is an exciting achievement, highlighting the tremendous unmet need for novel therapies to treat solid tumor cancers and the role that ST101 can play to fill this need," said Jim Rotolo, Ph.D., Sapience's VP, Translational Pharmacology and Head of Research. "We are thrilled to publish the mechanism of action of ST101 and showcase the therapeutic promise of disrupting C/EBP-driven oncogenic activity. We look forward to reporting and publishing additional data on ST101 and advancing the program through its ongoing Phase 1-2 study."

In its ongoing Phase 1-2 study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM, a durable RECIST 1.1-confirmed partial response in a patient with cutaneous melanoma and long-lasting stable disease in several additional patients.

About ST101 and the Phase 1-2 StudyST101, a first-in-class antagonist of C/EBP, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). ST101-101 is an open-label, Phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with advanced solid tumors. The study consists of two phases: Phase 1 dose escalation/regimen exploration and Phase 2 dose expansion. In the ongoing Phase 2 dose expansion, Sapience is actively enrolling patients with GBM, metastatic cutaneous melanoma, castration-resistant prostate cancer and locally advanced or metastatic hormone-receptor positive breast cancer. In the ongoing dose escalation part of the study, ST101 has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. In the ongoing Phase 2 dose expansion part of the study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM and evidence of long-lasting stable disease in several additional patients.

ST101 has been granted Fast Track designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy,as well as orphan designations from the FDA for advanced melanoma, glioma and AML, and from the European Commission for the treatment of glioma.

About Sapience TherapeuticsSapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Its pipeline of SPEARs (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience's lead program, ST101, is a first-in-class antagonist of C/EBP that has demonstrated clinical proof-of-concept in multiple indications. For more information on Sapience Therapeutics, please visitwww.sapiencetherapeutics.comand engage with us onLinkedIn.

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.

ContactsSapience Therapeutics, Inc.Barry Kappel, Ph.D., M.B.A.President and Chief Executive Officer[emailprotected]

Media and Investor Contact:Amy ConradJuniper Point(858) 366-3243[emailprotected]

SOURCE Sapience Therapeutics

Read the original here:
Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide...

Biotechnology engineering is an undergraduate degree programme in applied sciences that amalgamates the facts from both Biological sciences and technology. This study utilizes the biological processes which include the study of microorganisms or knowledge of antibiotics and further implement them in various industrial purpose.

In simple terms, Biotechnology is a study which involves the use of living organisms. The living organisms are used to make useful chemicals which can be utilized in industries. Biotechnological products are used in areas like agriculture, food sciences and medicine.

Biotechnology engineers tend to work with a broad range of medical, technical and admin professionals. The key skillsets include:

The minimum eligibility criteria required in order to pursue a BTech programmein Biotechnology states that a candidate should have completed their + 2 education with PCB. While there are engineering institutes that consider Mathematics a compulsory subject in order to offer admissions to candidates, institutes like JNU does not make maths mandatory for seeking admissions into the BTech in Biotechnology programmes. Candidates who have studied Biology in +2 can also apply for admissions.

The syllabus and course curriculum for BTech in Biotechnology vary for each university. However, we have enlisted a general list of topics included in the course programmes.

Subjects

Topics

Objective

Inorganic chemistry

Chemical bonding

Acids and Bases

Catalysis

Polymers

Colloids

This course introduces the concepts of inorganic chemistry.

Foundation course in physics

Interference by the division of wavefront

Diffraction

Polarization

Introduction to lasers

Fibre optical

This course is designed to provide fundamental knowledge of theories and concepts in physics.

Life sciences

Origin of life

Histology

Nutrition

Energy utilization

This course focuses on the discipline of Life Sciences and concepts related to it.

Essential in mathematics

Algebra of matrices

Quadratic forms

Mean value theorems

Partial derivatives

Mathematics is an essential part of the core curriculum for engineering courses.

Concepts in biotechnology

Introduction to biotechnology

Protein structure and engineering

Plant cell culture

This course introduces to the discipline of biotechnology and explains some of the basic concepts of biotechnology.

Introduction to computers

Introduction

Data storage

Programming using C

In this course, students learn the basics of computer and programming languages.

Foundation course in organic chemistry

Electronic displacements

Reactive intermediaries

Stereochemistry

Organic Chemistry is an important subject in Biotechnology. This course explains the basic ideas in organic chemistry.

Life sciences

Coordination and control

Homeostasis

Asexual reproduction

This course intends to study Life Science in a broader horizon.

Electric sciences

Properties of conductor and insulators

Alternating currents

Measuring instruments

Transformers

This paper focuses on the basic concepts of electronics and electrical science.

Microbiology

Microbes in human life

Functional anatomy

Microbial growth

Microbiology is another important paper for Biotechnology. It introduces topics and concepts of microbiology.

Bioenergetics

Biochemical evolution

Carbohydrates

Nucleic acids

Lipids

This course focuses on the study of energy flow through living systems.

Cell biology

Cell

Nucleus

Cell signalling

Cell cycle and division

This course intends to study the structure and function of living cells.

Chemical engineering

Chemical equations

Hearts of solution

The flow of incompressible fluids

This course focuses on the basic concepts of chemical engineering.

Molecular biology

Structure and properties of nucleic acids

DNA replication

Gene mutation

This paper aims to study biological activity at the molecular level.

Enzyme technology

Introduction to enzymes

Specificity of enzymes

Immobilization of enzyme

Enzyme technology is a subfield of biotechnology. This course introduces the concepts and theories of this field.

Plant tissue culture

Cellular totipotency

Cell and suspension culture

Protoplast culture

Haploid culture

This course studies techniques used to maintain or grow plant cells, tissues or organs artificially in a lab.

Animal biotechnology

See original here:
Higher Education in India | Shiksha.com

On August 16, 2018, the NIH Director issued a statement describing a proposal to streamline the federal framework for oversight of gene therapy. This proposal, which was developed in conjunction with the Food and Drug Administration, included amending the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) to eliminate duplicative review and reporting requirements for human gene transfer protocols. The statement also describes NIHs effort to refocus the role of the NIH Recombinant DNA Advisory Committee (RAC) to be closer to its original mandate a transparent forum for science, safety, and ethics of emerging biotechnologies. After a 60-day public comment period, the NIH Guidelines have been updated to reflect these changes and the RAC has been renamed the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC).

The charter of the NExTRAC reflects the shift in focus of the committee while embracing the continuity of this important advisory committee.

Federal Register Notice

Charter of the NExTRAC

NIH Directors Statement

Under the Poliscope Blog

NIH Guide to Grants and Contracts Notice

More here:
NIH Guidelines - National Institutes of Health

HSINCHU, Sept. 11, 2022 /PRNewswire/ --Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines.

NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes.

"We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," said Sherif Bayoumy, the General Manager of Medtreq Medical Equipment.

The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technologyto make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level."

About Metreq Medical Equipment Bahrain

Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity.

About Brain Navi

Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.

SOURCE Brain Navi Biotechnology Co., Ltd.

View original post here:
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac...

LOS ANGELES, September 11, 2022--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology (ESMO) Congress, currently taking place in Paris, France. The poster (#559P) entitled, "Neratinib in HER2-mutant, recurrent/metastatic cervical cancer: updated findings from the phase 2 SUMMIT basket trial," was presented by Claire F. Friedman, M.D., Melanoma and Immunotherapy Service, Memorial Sloan Kettering Cancer Center, on September 11 at 11:10 a.m. CEST.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220911005034/en/

The Phase II SUMMIT basket trial is an open-label, multicenter, multi-national study evaluating the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating, somatic HER2 mutations. The cervical cancer cohort was comprised of 22 patients with persistent, recurrent, or metastatic cervical cancer and a HER2 mutation, as documented by institutional testing at a CLIA/CAP- (or regionally equivalent) certified laboratory. Patients were treated with neratinib monotherapy (240 mg/day); 22 patients (100%) had previously received platinum-based chemotherapy, 16 patients (73%) had prior bevacizumab, and 4 patients (18%) received prior pembrolizumab. Overall, the objective response rate was 18.2% (95% CI: 5.240.3%) and the clinical benefit rate was 45.5% (95% CI: 24.467.8%), which included 1 patient with a confirmed complete response, 3 patients with confirmed partial responses, and 6 patients with stable disease at equal or greater than 16 weeks. The median progression-free survival was 5.1 months (95% CI: 1.77.2 months). Among the 13 patients (59.1%) who had tumors with a highly activating HER2 S310F/Y mutation, 4 had confirmed responses.

Story continues

The safety profile observed in the neratinib-treated cervical cancer patients was consistent with that reported for neratinib monotherapy in HER2-amplified breast cancer. The most frequently observed treatment-related adverse event was any-grade diarrhea (n=18; 81.8%), which included 5 (22.7%) Grade 3 or higher diarrhea events. Diarrhea was manageable with anti-diarrheal prophylaxis and none of the diarrhea events resulted in dose reduction or treatment discontinuation.

"HER2 mutations are present in 5% of cervical cancers, most commonly in endocervical adenocarcinomas, and HER2 targeted therapy is a potential treatment option for patients whose cancer has grown after standard first lines of treatment, including platinum-based chemotherapy," said Dr. Friedman, an investigator of the study from Memorial Sloan Kettering Cancer Center. "Neratinib treatment has been effective against several HER2-mutant cancers and the observed durable responses and disease control in metastatic patients with HER2-mutant cervical cancer are extremely promising for patients."

Alan H. Auerbach, CEO and President of Puma Biotechnology, added, "We are very pleased to observe that treatment with neratinib led to durable response and effective disease control in patients with aggressive HER2-mutant cervical cancer and that the adverse event of diarrhea could be managed with prophylaxis. Improving the lives of our cancer patients is our foremost goal, and we are pleased to see the benefit that was provided to these patients in the SUMMIT trial."

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at https://www.NERLYNX.com or 1-855-816-5421.

INDICATIONS:

NERLYNX (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.

In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2 based regimens in the metastatic setting.

IMPORTANT SAFETY INFORMATION Regarding NERLYNX (neratinib) U.S. Indication:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

Diarrhea: Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade 2 diarrhea that occurs after maximal dose reduction.

Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common adverse reactions (reported in 5% of patients) were as follows:

NERLYNX as a single agent: Diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

NERLYNX in combination with capecitabine: Diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

DRUG INTERACTIONS:

Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists. Or separate NERLYNX by at least 3 hours with antacids.

Strong CYP3A4 inhibitors: Avoid concomitant use.

P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.

Strong or moderate CYP3A4 inducers: Avoid concomitant use.

Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with NERLYNX.

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the development of Pumas product candidates. All forward-looking statements involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent reports. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220911005034/en/

Contacts

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500info@pumabiotechnology.com ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1-212-845-4271david.schull@russopartnersllc.com olipriya.das@russopartnersllc.com

View original post here:
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer...

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will participate virtually in the UBS Biotechnology Private Company Symposium, being held September 21-22, 2022. Pipeline will present a company overview and will conduct virtual one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials - a SAD/MAD study and a PET study - in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit http://www.pipelinetherapeutics.com and engage with us on LinkedIn.

Link:
Pipeline Therapeutics to Participate in the UBS Virtual Biotechnology Private Company Symposium - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24th Annual Global Investment Conference, which will be held September 12-14, 2022. The virtual presentation will be available for 30 days beginning at 7:00 a.m. EDT on September 12, 2022 on the Companys website at https://www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View post:
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Business Wire

Did you know Wilson Community College offers a two-year degree in biotechnology?

This field is designed to meet the ever-increasing demands for skilled lab technicians in a wide range of fields in biological and chemical technology. So if you find yourself interested in the sciences, this is a great option to explore. The program focuses on biological sciences, biochemistry and genetics.

The biotechnology program at WCC includes a diverse group of students, including traditional students, early college students and high school students. Biotechnology students attending the Wilson Academy of Applied Technology, one of our early colleges, not only earn a high school diploma, but they also get a two-year degree at the same time. And we also partner with the Sallie B. Howard School of Art & Science to provide biotechnology courses to juniors and seniors as part of the College and Career Promise program.

WCCs biotechnology instructor, Stephanie Winstead, has a degree in chemistry and has work experience in the pharmaceutical industry a win-win for our students. She knows firsthand the importance of and the need for skilled workers in this field.

After 17 years in the pharmaceutical industry, and as my career evolved from a training role to a more administrative role, I realized my passion was teaching, she said. While my career has changed, my goal is the same. I now have the opportunity to train personnel for the job they want, rather than training them for the job they have. I am committed to giving students the skills necessary to successfully gain employment in the biotech field upon graduation. I am incredibly thankful for the privilege of serving the needs of my community.

And to add to that, we just received some exciting news. The North Carolina Community College System just announced that it was awarded $16.4 million over three years in federal funding to implement the N.C. BioBetter project. This is part of the U.S. Economic Development Administration Phase 2 Build Back Better Regional Challenge spearheaded by the N.C. Biotechnology Center.

The funding, awarded to Wilson Community College and nine other community colleges in the state, will help strengthen our states life sciences manufacturing cluster by expanding training and helping promote career opportunities to underserved communities.

With careers in biotechnology, the skys the limit. Graduates are qualified in all kinds of industry and government, including research, manufacturing and sales, just to name a few. We work with some of our local industries like Merck & Co., Purdue Pharma, Fresenius Kabi, Mayne Pharma and Global Laboratory Services Inc. Side note: Global Laboratory Services is not pharma, but rather agricultural biotechnology. We have students doing work-based learning with the company as crop protection agents, and Global Laboratory Services has recently hired one of our biotech graduates with hopes to hire more. And we also have an apprenticeship program with GlaxoSmithKline in Zebulon.

But to be more specific, here are the different types of work available. Graduates will be able to do the following:

Monitor or measure manufacturing processes to identify ways to reduce losses, decrease time requirements or improve quality.

Conduct routine and non-routine analyses of in-process materials, raw materials, environmental samples, finished goods or stability samples.

Interpret test results, compare them to established specifications and control limits and make recommendations on appropriateness of data for release.

Compile laboratory test data and perform appropriate analyses.

Complete documentation needed to support testing procedures, including data capture forms, equipment logbooks or inventory forms.

If youd like more information about the biotechnology program, contact Stephanie Winstead, biotechnology instructor, at swinstead@wilsoncc.edu, or Travis Flewelling at tflewelling@wilsoncc.edu or 252-246-1210. At #WilsonCC, we make Wilson work.

WHATS HAPPENING

Sept. 14 New student orientation.

Sept. 19 Community chorus practice at 7 p.m.

Sept. 24 WCC Car & Truck Show from 9 a.m. to 3 p.m.

Jessica Griffin is director of institutional advancement at Wilson Community College. She can be reached at jgriffin@wilsoncc.edu or 252-246-1271.

Visit link:
WCC Corner: Interested in the sciences? How about biotechnology? - Restoration NewsMedia

New Jersey, United States, Sept. 4, 2022 /DigitalJournal/ Cellular reprogramming is the process of reverting mature and specialized cells into induced pluripotent stem cells. Reprogramming also refers to the erasure and resetting epigenetic marks during mammalian germ cell development. Stem cells are studied and developed in treatments for various ailments using cell reprogramming methods, as a method of replenishing cells damaged by disease. These cells are created from somatic cells, such as blood or skin cells, that have undergone genetic reprogramming to resemble embryonic stem cells to produce an endless supply of a wide variety of human cells for therapeutic purposes.

The Cell Reprogramming Market research report provides all the information related to the industry. It gives the markets outlook by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments, and manufacturing technology. This Cell Reprogramming market research report tracks all the recent developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

https://a2zmarketresearch.com/sample-request

Competitive landscape:

This Cell Reprogramming research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status, and upcoming products.

Some of the Top companies Influencing this Market include:Allele Biotechnology, ALSTEM, Applied Biological Materials, Axol Bioscience, Creative Bioarray, DefiniGEN, Fujifilm Cellular Dynamics, Lonza, Mogrify, REPROCELL, Stemnovate, Thermo Fisher Scientific

Market Scenario:

Firstly, this Cell Reprogramming research report introduces the market by providing an overview that includes definitions, applications, product launches, developments, challenges, and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristics is provided in the Cell Reprogramming report.

Regional Coverage:

The region-wise coverage of the market is mentioned in the report, mainly focusing on the regions:

Segmentation Analysis of the market

The market is segmented based on the type, product, end users, raw materials, etc. the segmentation helps to deliver a precise explanation of the market

Market Segmentation: By Type

Sendai Virus-based ReprogrammingmRNA ReprogrammingEpisomal ReprogrammingOthers

Market Segmentation: By Application

Research & Academic InstitutesBiotechnology & Pharmaceutical CompaniesHospitals & Clinics

For Any Query or Customization: https://a2zmarketresearch.com/ask-for-customization

An assessment of the market attractiveness about the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants in the global Cell Reprogramming market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.

This report aims to provide:

Table of Contents

Global Cell Reprogramming Market Research Report 2022 2029

Chapter 1 Cell Reprogramming Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cell Reprogramming Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4157

Read the original:
Cell Reprogramming Market is Expected to Record the Massive Growth, with Prominent Key Players Allele Biotechnology, ALSTEM, Applied Biological...

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media.

With one of the highest concentrations of high-quality startups in the world, Israel has built a global reputation, rightfully earning the nickname of 'startup nation'. Industries ranging from agriculture, technology, healthcare, and more, have benefitted from the immense levels of innovation coming from Israel. In an attempt to become self-reliant, Israel invested in infrastructure, education, and technology to empower innovative leaders and field experts to lead the charge in their respective industries.

Biotechnology is one of Israel's most dominant sectors, with life science companies raising nearly $7 billion in the last decade on the NASDAQ. Israel's clear prominence in this industry has led major companies such as Pfizer, GE, Johnson & Johnson and more, to build R&D centers and startup incubators in the country. Garnering recognition on a global scale, helping other countries solve their own problems, and cultivating innovation within its own borders have propelled Israel to the center of biotech, and this is just the beginning.

What sets Israel apart

In the healthcare sector, many countries have failed to update medical procedures, opting for traditional, outdated approaches that fail to optimize procedures and client experiences. Israel is setting a new standard by showcasing the value of innovation and technology in medicine. For instance, the Israel-based company Nanox, which uses AI to redefine the landscape in early medical detection, had the largest IPO of any young medical company in history in 2020. This is just one example of how Israel has fostered innovation in biotech.

There are many factors that play into Israel's ambitious successes in biotechnology, but top-notch education and high levels of R&D investment are two of the most notable. Israel spends roughly 6 per cent of its GDP on education, and its academic institutions foster creative learning, innovation and technology for their students at all levels.

With educated citizens, grand investments in R&D, and an ever-changing landscape of need, Israel is poised to serve as a leader in biotechnology for the foreseeable future. Global landscapes across several industries are changing thanks to Israel's commitment to cutting-edge advancements in biotech.

Advancing the future of meaty technology

As more consumers grow weary of the potential health risks, environmental impact, and animal cruelty aspect of eating meat, alternative options are taking form at a rapid pace. Aleph Farms is the world's first company to produce steaks from animal cells. Recently, they announced that will join the Agriculture Innovation Mission for Climate (AIM for Climate) as an Innovation Sprint Partner.

Aleph Farms sees cellular agriculture as a practical solution to the world's most urgent issues and is working on developing affordable cell growth media for cultivated meat production, as well as conducting groundbreaking experiments on cultivated meat in space.

Revolutionizing Spinal Cord Treatment

There are between 250,000 and 500,000 new spinal cord injuries each year, according to the World Health Organization (WHO). These injuries are largely irreversible, leaving patients with costly medical care needs, extensive therapy treatments, and not much hope. Cutting-edge biotechnology is being developed to offer patients treatment that could restore some of the lost function.

NurExone, an Israel-based biotechnology company uses exosome technology to deliver proprietary agents that have the potential to support nerve regeneration. NurExone's studies show that their technology can create significant functional improvements. In one of their studies, they showed how animals who were able to walk again due to their treatment. NurExone's technology has been shown to stimulate nerve regeneration all while being non-invasive something quite revolutionary. Although they are still early-on in their journey, NurExone is reigniting treatment approaches for spinal cord injuries (SCI). With the total market for spinal cord trauma expected to reach $3.04 billion by 2025, NurExone's is tackling a large issue and brining hope to SCI patients around the world.

Treating cancer with precision medicine

Every patient is different, and Imagene AI is making it possible to treat them as such. With digitized biopsy imaging, Imagene AI can offer real-time molecular analysis to cancer patients, reducing the normal lead time from two weeks to two minutes. This level of innovation is astounding, but Imagene AI takes it even further. With wide-scope treatment-response prediction, medical professionals can gain an understanding of how each patient's body will respond to a variety of treatment plans.

A recent investment round brought in $21.5 million, with $18.5 million coming from Oracle co-founder Larry Ellison, and his fellow investors Dr. David Angus and Eyal Gura. At only two years old, Imagene AI has already begun changing the landscape of cancer treatment.

Biotech innovation addresses humanity's biggest problems

With Israel, the hub of innovation, leading the charge, the future is bright for biotechnology and the impact it will have on the world. While many medical needs can be addressed with the right advancements in the industry, it is becoming more clear that igniting growth in the biotech industry will bring abundant benefits to many other industries that need to be propelled into the future.

More here:
Israeli Companies Are Leading the Global BioTech Charge, Here's How And Why - Entrepreneur

Felix awarded competitive NIH grant to build a microfluidics platform which will accelerate generalizable phage therapy.

Bacteriophage, or phage, are natural predators of bacteria with enormous potential to treat bacterial infections, but most only kill a narrow range of bacteria which limits their clinical potential. To reach the clinic, Felix is engineering phage to kill a broader range of bacteria, and this requires large amounts of data on phage-bacteria interactions. Supported by this SBIR grant, Felix will develop new tools that accelerate the acquisition of this critical phage-bacteria interaction data.

"We are excited to apply the high throughput tools that have been developed in the microfluidics space to address the constraints that limit phage data collection," said UCSF professor Adam Abate, world-renowned microfluidics expert and collaborator on this project. Professor Abate continues, "With microfluidics we can generate the large amount of data needed to leverage the power of machine learning approaches to identify how to engineer viruses to kill a broader range of bacteria."

"Phage therapy has been around for a long time but has not reached its potential due to the narrow host ranges of most therapeutic phages. The tools being developed in this grant will allow us to overcome this key technical limitation and develop generalizable phage therapy to effectively treat antimicrobial resistant infections and save lives," said Rob McBride, co-founder of Felix.

As the incidence of deadly antimicrobial infections increases globally, Felix remains at the forefront of global efforts to create novel and effective solutions. Felix thanks the NIH and other funders for their generous support and efforts to shape a better future for global health.

About Felix Biotechnology

Felix Biotechnology is focused on discovering, developing and deploying customizable antimicrobials targeting urgent microbial threats. Felix's discovery and engineering technology platforms, built on technology from Yale University and Lawrence Berkeley National Laboratory, generate solutions that overcome the key limitations of traditional antimicrobials to kill targeted bacteria while preserving healthy microbiome function. Felix is a seed stage company funded by multiple investors, including Y Combinator, Illumina Accelerator and Point72 Ventures. More information is available at http://www.felixbt.com.

For more on Felix Biotechnology, please visit: https://www.felixbt.com/

For more on the Adam Abate lab, please visit https://www.abatelab.org/

For more on the National Science Foundation's Small Business Programs, please visit: https://seedfund.nsf.gov/

SOURCE Felix Biotechnology, Inc.

Original post:
Felix Biotechnology Awarded Competitive Grant from the National Institutes of Health to Power Phage Engineering Platform - PR Newswire